The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

The S&P 500 ended 2024 with a 25% gain for the year. This marks the second consecutive year of gains exceeding 25% and the third such occurrence in the past four years.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

The weakness was also weighing on shares of some of Walmart's rivals, as Costco Wholesale Corp.'s stock (COST) fell 2.2% and Target Corp. shares (TGT) shed 1.1%, to underperform the S&P 500 index's ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.